Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

Florian Lordick(Leipzig University), Christian Wittekind(University Hospital Leipzig), Miriam Ahlborn(Klinikum Braunschweig), Stefan Fuxius(Praxis für Hämatologie und Onkologie), Dieter Maier(Boehringer Ingelheim (Germany)), Jan Hasenauer(University of Bonn), Katrin Schierle(University Hospital Leipzig), Gabriele Margareta Siegler(Nuremberg Hospital), Birgit Luber(Technical University of Munich), Ivonne Haffner(Leipzig University), Beate Rau(Medizinische Hochschule Hannover), Jorge Riera Knorrenschild(Philipps University of Marburg), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Elba Raimúndez(Helmholtz Zentrum München), Albrecht Kretzschmar(Roche (Switzerland)), Thomas Decker
Cancer Research
July 1, 2018
10.1158/1538-7445.am2018-2615
Cited by 5

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k